Peptomyc, a CataloniaBio & HealthTech member, has received €2.2 million in funding from the second phase of the SME Instrument, under the EU Horizon 2020 programme, to start clinical trials with its new cancer therapy Omomyc. 

Omomyc is the best inhibitor discovered to date of Myc, a gene that is key in the growth of most tumours. The results from studies in mice have been positive.

Founded in 2014 by Dr Laura Soucek and Dr Marie-Eve Beaulieu, Peptomyc is a promising spin-off of the Vall d’Hebron Institute of Oncology and ICREA. In 2017, the company raised €4.2 million in Series-A funding, through a round led by Alta Life Sciences.

We recommend this video of CataloniaBioHT interviewing them: